Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -7,7 +7,6 @@
7	7	* AbCellera works on the development of therapeutic antibodies.
8	8	* AbCellera partner with drug developers of all sizes to push therapeutic programs forward and fight disease.
9	9
10		-
11	11	[[image:ABCL0.jpg||height="342" width="719"]]
12	12
13	13
...	...	@@ -56,7 +56,7 @@
56	56
57	57	== Full year 2021 Result. ==
58	58
59		-The company generated revenue of $233.2 million and $375.2 million for the years ended December 31, 2020 and 2021, respectively. As of December 31, 2021, the company had a total of 36 partners for whom the company were conducting antibody discovery activities. For the year ended December 31, 2020, three of its partners accounted for35%, 25% and 14% of its research fees revenue and eight partners accounted for the remaining 26% of research fees revenue. For the year ended December 31,2020 the company recognized its first clinical milestone payments and royalty revenue streams, totaling $213.3 million, exclusively from its partnership with Lilly. For the year ended December 31, 2021, four of its partners accounted for 29%, 17%, 11% and 10% of its research fees revenue and 12 partners accounted for the remaining 33% of research fees revenue. For the year ended December 31, 2021, the company recognized milestone payments of $7.0 million and royalty revenue of $327.3million exclusively from its partnership with Lilly.
	58	+The company generated revenue of $233.2 million and $375.2 million for the years ended December 31, 2020 and 2021, respectively. As of December 31, 2021, the company had a total of 36 partners for whom the company was conducting antibody discovery activities. For the year ended December 31, 2020, three of its partners accounted for 35%, 25% and 14% of its research fees revenue and eight partners accounted for the remaining 26% of research fees revenue. For the year ended December 31,2020 the company recognized its first clinical milestone payments and royalty revenue streams, totaling $213.3 million, exclusively from its partnership with Lilly. For the year ended December 31, 2021, four of its partners accounted for 29%, 17%, 11% and 10% of its research fees revenue and 12 partners accounted for the remaining 33% of research fees revenue. For the year ended December 31, 2021, the company recognized milestone payments of $7.0 million and royalty revenue of $327.3million exclusively from its partnership with Lilly.
60	60
61	61
62	62	The company incurred research and development expenses of$29.4 million and $62.1 million for the years ended December 31, 2020 and 2021, respectively. The company incurred general and administrative expenses of $11.9 million and $41.8 million for the years ended December 31, 2020 and 2021, respectively.